Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Enliven Therapeutics Inc shares valued at $133,993 were sold by Patel Anish on Oct 07 ’25. At $20.10 per share, Patel Anish sold 6,667 shares. The insider’s holdings dropped to 276,641 shares worth approximately $6.01 million following the completion of this transaction.
Also, Hohl Benjamin sold 3,250 shares, netting a total of over 66,291 in proceeds. Following the sale of shares at $20.40 each, the insider now holds 23,000 shares.
Before that, Lyssikatos Joseph P had sold 4,000 shares from its account. In a trade valued at $81,005, the CHIEF SCIENTIFIC OFFICER traded Enliven Therapeutics Inc shares for $20.25 each. Upon closing the transaction, the insider’s holdings decreased to 4,000 shares, worth approximately $20.16 million.
As published in their initiating research note from Goldman on June 16, 2025, Enliven Therapeutics Inc [ELVN] has been a Buy and the price target has been revised to $37. Analysts at BTIG Research started covering the stock with ‘”a Buy”‘ outlook in a report released in mid December. As of September 09, 2024, H.C. Wainwright has initiated its “Buy” rating for ELVN. Earlier on June 11, 2024, Robert W. Baird initiated its rating. Their recommendation was “an Outperform” for ELVN stock.
Analyzing ELVN Stock Performance
On last trading session, Enliven Therapeutics Inc [NASDAQ: ELVN] rose 8.11% to $21.73. The stock’s lowest price that day was $20.19, but it reached a high of $21.75 in the same session. During the last five days, there has been a surge of approximately 6.94%. Over the course of the year, Enliven Therapeutics Inc shares have dropped approximately -22.14%.
Is Enliven Therapeutics Inc subject to short interest?
Stocks of Enliven Therapeutics Inc saw a sharp rise in short interest on 2025-09-30 jumping by 0.81 million shares to 5.7 million. Data from Yahoo Finance shows that the short interest on 2025-08-29 was 4.89 million shares. A jump of 14.18% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 9.59 of the overall float, the days-to-cover ratio (short ratio) jumped to 9.59.
Which companies own the most shares of Enliven Therapeutics Inc (ELVN)?
In terms of Enliven Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 52 in the next 12 months, up nearly 158.71% from the previous closing price of $20.1. Analysts anticipate Enliven Therapeutics Inc stock to reach 52 by 2025, with the lowest price target being 52. In spite of this, 0 analysts ranked Enliven Therapeutics Inc stock as nan at the end of 2025. On April 09, 2024, Mizuho assigned a price target of “a Buy” to the stock and initiated coverage with a $34.
